Market capitalization | $11.80m |
Enterprise Value | $4.18m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.76 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-26.61m |
Free Cash Flow (TTM) Free Cash Flow | $-19.47m |
Cash position | $11.89m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
4 Analysts have issued a IN8bio Inc forecast:
4 Analysts have issued a IN8bio Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.45 -2.45 |
4%
4%
|
|
EBITDA | -24 -24 |
15%
15%
|
EBIT (Operating Income) EBIT | -27 -27 |
14%
14%
|
Net Profit | -27 -27 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Head office | United States |
CEO | William Ho |
Employees | 18 |
Founded | 2016 |
Website | www.in8bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.